Infant Bacterial Therapeutics publishes Annual Report for 2021 in XHTML format
January 27, 2023 08:55 ET | Infant Bacterial Therapeutics AB
On March 31 2022 IBT published the 2021 annual report in the format of a PDF file. Today, IBT publish the same report in the XHTML format. The content of the report has not been changed. see...
Infant Bacterial Therapeutics publicerar Årsredovisning för 2021 i XHTML format
January 27, 2023 08:55 ET | Infant Bacterial Therapeutics AB
Den 31 mars 2022 publicerade IBT sin årsredovsning för 2021. Filformatet som då användes var PDF. Idag publicerar IBT samma rapport i XHTML format. Innehållet i rapporten har inte ändrats. se...
jotul.png
Interim Financial Report Third quarter ended 30 September 2022
November 30, 2022 02:30 ET | Jøtul AS
YTD Q3 2022, the Jotul Group reached a consolidated profit of MNOK 4.5 (YTD Q3 2021: loss of MNOK 57.5). The operating profit totaled MNOK 95.5 in YTD Q3 2022 (YTD Q3 2021: MNOK 12.9). The 2022 total...
CTMnew
Castellum, Inc. Announces Strong Third Quarter Financial Results Including Record Revenue
November 15, 2022 06:55 ET | Castellum, Inc.
BETHESDA, Md., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Castellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, data analytics, software, and IT services company focused...
Inventiva reports 2022 Third Quarter Financial Information¹
November 10, 2022 16:00 ET | INVENTIVA
Cash position2 at €72.6m as of September 30, 2022, not including the $12.6 million upfront payment received from Sino Biopharm on November 4, 2022Revenues of €0.1m for the first nine months of 2022 ...
Inventiva publie ses informations financières du 3ème trimestre 2022¹
November 10, 2022 16:00 ET | INVENTIVA
Position de trésorerie2  à 72,6 M€ au 30 septembre 2021 , sans prise en compte du paiement de 12,6 M$ reçu le 4 novembre de la part de Sino BiopharmChiffre d’affaires de 0,1 M€ sur les neuf premiers...
Infant Bacterial Therapeutics AB (publ) (IBT), Interim Management Statement, July 1 – September 30, 2022 
November 10, 2022 02:00 ET | Infant Bacterial Therapeutics AB
Message from the CEO Our IBP-9414 clinical phase III development project is progressing well, and as previously mentioned, we are pursuing several initiatives to accelerate study execution. It is...
Infant Bacterial Therapeutics AB (publ) (IBT), delårsrapport 1 juli – 30 september 2022
November 10, 2022 02:00 ET | Infant Bacterial Therapeutics AB
VD kommenterar Vårt utvecklingsprojekt IBP-9414 i klinisk fas III fortskrider väl, och som jag tidigare nämnt arbetar vi med flera aktiviteter för att påskynda genomförandet av vår studie. Det är...
jotul.png
Jøtul Group - Interim financial report for the half-year ended 30. June 2022
August 26, 2022 04:30 ET | Jøtul AS
In the first half of 2022, the Jotul Group reached a consolidated profit of MNOK 15.2 (H1 2021: loss of MNOK 54.1). The operating profit totaled MNOK 65.4 in H1 2022 (H1 2021: loss of MNOK 1.2). The...
Pieridae logo_Hunter.jpg
Pieridae to Hold Conference Call and Webcast on Q2 2022 Results
July 12, 2022 08:00 ET | Pieridae Energy Limited
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN UNITED STATESCALGARY, Alberta, July 12, 2022 (GLOBE NEWSWIRE) -- Pieridae Energy Limited (“Pieridae” or the “Company”)...